

Oral maribavir for treatment of refractory or resistant cytomegalovirus infection in transplant recipients

Transplant Infectious Disease

12, 489-496

DOI: [10.1111/j.1399-3062.2010.00550.x](https://doi.org/10.1111/j.1399-3062.2010.00550.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America, 2010, 24, 809-833.	1.9	71
2	Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America, 2010, 24, 413-437.	1.9	161
3	Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed?. Current Opinion in Virology, 2011, 1, 555-562.	2.6	81
5	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infectious Diseases, The, 2011, 11, 284-292.	4.6	315
6	Why did maribavir fail in stem-cell transplants?. Lancet Infectious Diseases, The, 2011, 11, 255-257.	4.6	16
8	Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. Pediatric Transplantation, 2011, 15, 229-236.	0.5	23
9	The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Research, 2011, 92, 364-368.	1.9	68
11	The biology of cytomegalovirus drug resistance. Current Opinion in Infectious Diseases, 2011, 24, 605-611.	1.3	89
12	Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future. Hematology American Society of Hematology Education Program, 2011, 2011, 305-309.	0.9	75
13	Cytomegalovirus Infection in Liver Transplant Recipients. Infectious Diseases in Clinical Practice, 2012, 20, 32-41.	0.1	0
14	Evaluation of infections in the lung transplant patient. Current Opinion in Infectious Diseases, 2012, 25, 193-198.	1.3	16
15	Case Report. Transplantation, 2012, 93, e30-e32.	0.5	9
16	Cytomegalovirus infection in solid organ transplantation. Enfermedades Infecciosas Y Microbiología Clínica, 2012, 30, 57-62.	0.3	6
17	Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial. American Journal of Transplantation, 2012, 12, 3021-3030.	2.6	115
18	Antiviral treatment of cytomegalovirus infection: an update. Expert Opinion on Pharmacotherapy, 2012, 13, 623-627.	0.9	25
19	Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opinion on Biological Therapy, 2012, 12, 1161-1172.	1.4	27
20	Successful Treatment of Pneumonia caused by <i>Aspergillus terreus</i> and Cytomegalovirus after Chemotherapy for Acute Myelogenous Leukemia. Infection and Chemotherapy, 2012, 44, 26.	1.0	2
21	Cytomegalovirus Infection and the Gastrointestinal Tract. Current Gastroenterology Reports, 2012, 14, 334-342.	1.1	73

#	ARTICLE	IF	CITATIONS
22	Management of multidrug-resistant viruses in the immunocompromised host. <i>British Journal of Haematology</i> , 2012, 156, 559-572.	1.2	29
23	Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. <i>Antiviral Research</i> , 2012, 95, 88-92.	1.9	27
24	Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients. <i>Current Infectious Disease Reports</i> , 2012, 14, 33-40.	1.3	32
25	Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. <i>BMC Infectious Diseases</i> , 2013, 13, 330.	1.3	30
26	Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation. <i>Clinical Microbiology Reviews</i> , 2013, 26, 703-727.	5.7	179
27	Clinical Aspects of Cytomegalovirus Antiviral Resistance in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1018-1029.	2.9	61
28	Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. <i>Transplantation Proceedings</i> , 2013, 45, 1603-1607.	0.3	43
29	Management Strategies for Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 317-342.	1.9	51
30	CMV: Prevention, Diagnosis and Therapy. <i>American Journal of Transplantation</i> , 2013, 13, 24-40.	2.6	220
31	Cytomegalovirus in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 93-106.	2.6	448
32	Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 137-146.	0.3	24
33	The ULbê2 Region of the Human Cytomegalovirus Genome Confers an Increased Requirement for the Viral Protein Kinase UL97. <i>Journal of Virology</i> , 2013, 87, 6359-6376.	1.5	23
34	Management of cytomegalovirus infection in haemopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 25-39.	1.2	92
35	Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity "is there a need for maribavir?. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 829-836.	0.5	0
36	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 96, 333-360.	0.5	651
37	Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1121-1126.	1.4	12
38	Cytomegalovirus Pneumonia in Hematopoietic Stem Cell Recipients. <i>Journal of Intensive Care Medicine</i> , 2014, 29, 200-212.	1.3	59
39	Treatment of cytomegalovirus infections beyond acute disease to improve human health. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 211-222.	2.0	24

#	ARTICLE	IF	CITATIONS
40	Cytomegalovirus Treatment. Current Treatment Options in Infectious Diseases, 2014, 6, 256-270.	0.8	56
43	Suspicion of Interaction Between Maribavir and Everolimus in a Renal Transplant Recipient. Transplantation, 2014, 98, e20-e21.	0.5	3
44	Uso exitoso de maribavir en un caso de colitis por citomegalovirus farmacorresistente en un paciente receptor de un trasplante cardiaco. Revista Espanola De Cardiologia, 2015, 68, 908-909.	0.6	1
45	Therapeutics to prevent congenital cytomegalovirus during pregnancy: what is available now and in the future?. Microbiology Australia, 2015, 36, 156.	0.1	7
46	Resistant cytomegalovirus infection in renal transplant recipients. Proceedings of Singapore Healthcare, 2015, 24, 243-248.	0.2	4
47	Combination therapy for multidrug-resistant cytomegalovirus disease. Transplant Infectious Disease, 2015, 17, 751-755.	0.7	19
48	Antivirals against Herpes Viruses. , 2015, , 546-562.e7.		5
49	Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. Computational and Structural Biotechnology Journal, 2015, 13, 153-158.	1.9	36
50	An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virology, 2015, 10, 113-134.	0.9	33
51	Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection. Journal of Virology, 2015, 89, 10230-10246.	1.5	14
52	Successful Use of Maribavir for Drug-resistant Cytomegalovirus Colitis in a Heart Transplant Recipient. Revista Espanola De Cardiologia (English Ed), 2015, 68, 908-909.	0.4	1
53	Antiherpesvirus Agents. , 2016, , 215-237.		0
54	CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016031.	0.5	47
55	Cytomegalovirus (CMV) Encephalitis in HIV Patients. Journal of Neurological Disorders, 2016, 04, .	0.1	0
56	How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood, 2016, 128, 2624-2636.	0.6	140
57	Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPi recommendations. Transplantation Reviews, 2016, 30, 119-143.	1.2	95
58	Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review. Journal of Clinical Virology, 2016, 82, 133-138.	1.6	11
59	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. Antiviral Research, 2016, 135, 91-96.	1.9	20

#	ARTICLE	IF	CITATIONS
60	Cytomegalovirus Infection After Stem Cell Transplantation. , 2016, , 417-440.		3
61	Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 603-630.	0.8	17
62	Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation, 2016, 100, e74-e80.	0.5	120
63	Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Reviews in Medical Virology, 2016, 26, 161-182.	3.9	53
64	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Annals of Hematology, 2016, 95, 1435-1455.	0.8	169
65	In vitro studies of the impact of maribavir on CMV-specific cellular immune responses. Journal of Clinical Virology, 2016, 75, 53-59.	1.6	9
66	Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review. Journal of Clinical Virology, 2017, 87, 12-16.	1.6	8
67	Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies. Clinics in Chest Medicine, 2017, 38, 295-305.	0.8	12
68	The human cytomegalovirus chemokine receptor homolog encoded by US27. Virus Genes, 2017, 53, 516-521.	0.7	3
69	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2484-2487.	1.0	14
70	Cytomegalovirus infection in lung transplant recipients. Expert Review of Respiratory Medicine, 2017, 11, 1-7.	1.0	14
71	Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients. Expert Review of Anti-Infective Therapy, 2017, 15, 93-110.	2.0	9
72	Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature. Pharmacotherapy, 2017, 37, 1258-1271.	1.2	27
73	Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 233-238.	0.6	78
74	Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients. Surgical Infections, 2017, 18, 128-136.	0.7	32
75	Prevention and treatment of bacterial infections in hematopoietic cell transplants. , 0, , 131-139.		0
76	Prevention and treatment of viral infections in hematopoietic cell transplants. , 0, , 140-151.		0
77	Overview of Infections Complicating Pediatric Hematopoietic Cell Transplantation. Infectious Disease Clinics of North America, 2018, 32, 237-252.	1.9	13

#	ARTICLE	IF	CITATIONS
78	The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. <i>Transplantation</i> , 2018, 102, 900-931.	0.5	784
79	Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, S72-S74.	0.6	11
80	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. <i>F1000Research</i> , 2018, 7, 661.	0.8	7
81	Pediatric transplantation case conference: Update on cytomegalovirus. <i>Pediatric Transplantation</i> , 2018, 22, e13276.	0.5	4
82	In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. <i>Antiviral Research</i> , 2018, 158, 255-263.	1.9	21
83	Antiviral Combination Therapy for Cytomegalovirus Infection in High-Risk Infants. <i>Antiviral Therapy</i> , 2018, 23, 505-511.	0.6	10
84	New Developments in the Management of Cytomegalovirus Infection After Transplantation. <i>Drugs</i> , 2018, 78, 1085-1103.	4.9	84
85	Infections in Hematopoietic Stem Cell Transplant Recipients. , 2018, , 195-230.		1
86	Antiviral Treatment and Prophylaxis in Immunocompromised Hosts. , 2018, , 317-337.		0
87	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. <i>Antiviral Research</i> , 2018, 157, 128-133.	1.9	40
88	Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 773-788.	1.3	14
89	Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975.		2
90	Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1017-1030.	1.0	29
91	Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. <i>New England Journal of Medicine</i> , 2019, 381, 1136-1147.	13.9	108
92	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , 2019, 163, 91-105.	1.9	66
93	Antimicrobial Drug Prophylaxis: Challenges and Controversies. , 2019, , 1123-1135.		0
94	Cytomegalovirus in solid organ transplant recipientsâ€™ Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13512.	0.8	418
95	Infection in Kidney Transplant Recipients. , 2019, , 517-538.		5

#	ARTICLE	IF	CITATIONS
96	Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 565-574.	1.3	10
97	Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 784-798.	1.0	9
98	Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1255-1264.	2.9	137
99	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 90-102.	1.2	27
100	Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation (Review). <i>Oncology Letters</i> , 2021, 21, 318.	0.8	5
101	Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475.		2
102	Letemovir. <i>Drugs of the Future</i> , 2013, 38, 291.	0.0	38
103	Viral Enteritis in Solid-Organ Transplantation. <i>Viruses</i> , 2021, 13, 2019.	1.5	9
105	Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus. <i>Therapeutics and Clinical Risk Management</i> , 2022, Volume 18, 223-232.	0.9	10
106	N-substitution Reactions of 2-Aminobenzimidazoles to Access Pharmacophores. <i>Current Organic Synthesis</i> , 2022, 19, .	0.7	0
107	Infectious Complications of Transplantation. , 2022, , 1627-1661.		1
108	Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations. <i>Annals of Pharmacotherapy</i> , 2023, 57, 597-608.	0.9	1
109	New Perspectives on Antimicrobial Agents: Maribavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	11
110	Therapie von Infektionen bei Tumorpatienten. <i>Springer Reference Medizin</i> , 2022, , 1-37.	0.0	0
111	Therapie von Infektionen bei Tumorpatienten. <i>Springer Reference Medizin</i> , 2023, , 1-37.	0.0	0
112	Maribavir. <i>Hospital Pharmacy</i> , 0, , 001857872211014.	0.4	0
113	Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 1144-1149.	2.8	8